Allakos Inc (ALLK) Stock Price, Quote & News

Company Profile

As of May 15, 2025, operates as a subsidiary of Concentra Biosciences, LLC.

Industry: Biotechnology

Sector: Healthcare

Phone: 650 597 5002

Website: www.allakos.com

Address:

825 Industrial Road, Suite 500, San Carlos, United States

Holymoly1269 Sep. 5 at 2:52 PM

$CMMB $ALLK

0 · Reply

nUme22 Jul. 30 at 12:43 PM

$ALLK money laundering scheme.. once done, they let these die in 3-5 yrs later . Thats it , nothing else

0 · Reply

Gainz4life Jun. 5 at 5:06 PM

$ALLK ive had this shit so long, but i didn't even realize it fell off my charts till today. $4500 gone. Fuck these guys.

0 · Reply

Swisstrad May. 28 at 1:37 PM

$ALLK question... what happen to traders who not sign - money lost?

0 · Reply

Estimize May. 19 at 10:00 AM

Wall St is expecting -0.30 EPS for $ALLK Q1 [Reporting 05/21 AMC] http://www.estimize.com/intro/allk?chart=historical&metric_name=eps&utm_c

0 · Reply

BEATWALLSTREET May. 16 at 9:07 PM

$ALLK what a scam this was. Raised close to one billion and sell it for 35 million

0 · Reply

Rage_Against_The_Machine May. 15 at 1:17 PM

$ALLK merger closes: Shareholders get $0.33 cash per share as Concentra takes control. Stock to be delisted effective today. Board resignations mark the end of an era for the once-promising biotech. For remaining holders, it's time to collect the check and move on. https://www.sec.gov/Archives/edgar/data/1564824/000114036125019156/ny20049047x1_8k.htm

0 · Reply

Love_To_Learn May. 15 at 10:32 AM

$ALLK finishing $STTO @zsk78 0.33**** which will be key today on all stocks in the market !

2 · Reply

WAYWARD_SUN May. 15 at 12:02 AM

$ALLK

0 · Reply

JrChase May. 14 at 9:05 AM

$GRYP is doing what $ALLK is doing… you can buy into ($ALLK) if you want…. $ALLK TARGET Projection $8🎯

0 · Reply

Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share

Mar 12, 2025, 4:02 PM EDT - 1 year ago

Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results

Feb 11, 2025, 11:30 AM EST - 1 year ago

Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

Feb 10, 2025, 5:36 PM EST - 1 year ago

Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm

Jan 27, 2025, 2:05 PM EST - 1 year ago

Why Is Allakos Stock Plunging On Monday?

Jan 27, 2025, 7:00 AM EST - 1 year ago

Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

Nov 7, 2024, 5:13 AM EST - 1 year ago

Allakos Runs Up Into A Near-Term Catalyst

Nov 6, 2024, 4:02 PM EST - 1 year ago

Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results

Oct 10, 2024, 4:02 PM EDT - 1 year ago

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

Jun 28, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Begins Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate

Jun 26, 2024, 9:15 PM EDT - 1 year ago

The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Engage

Jun 25, 2024, 4:02 PM EDT - 1 year ago

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

Jun 24, 2024, 6:50 PM EDT - 1 year ago

The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Join

Jun 23, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Starts Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate

Jun 22, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Get Involved

Jun 19, 2024, 4:15 PM EDT - 1 year ago

Claims Against Allakos Inc The Schall Law Firm Begins Probe And Urges Affected Investors To Participate

Jun 18, 2024, 4:00 PM EDT - 1 year ago

Allegations Against Allakos Inc The Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Get Involved

Jun 17, 2024, 5:00 PM EDT - 1 year ago

Claims Against Allakos Inc Schall Law Firm Begins Probe And Urges Affected Investors To Participate

Jun 11, 2024, 6:30 PM EDT - 1 year ago

Allegations Against Allakos Inc.: Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Get Involved

Jun 9, 2024, 11:00 AM EDT - 1 year ago

Charges Against Allakos Inc.: Schall Law Firm Launches Examination And Invites Affected Investors To Participate

Jun 8, 2024, 11:00 AM EDT - 1 year ago

Accusations Against Allakos Inc.: Schall Law Firm Begins Inquiry And Calls On Impacted Investors To Engage

Jun 7, 2024, 4:40 PM EDT - 1 year ago

Claims Against Allakos Inc.: Schall Law Firm Initiates Probe And Invites Affected Investors To Connect

Jun 6, 2024, 1:00 PM EDT - 1 year ago

Allegations Against Allakos Inc.: Schall Law Firm Begins Investigation And Encourages Impacted Investors To Reach Out

Jun 5, 2024, 1:45 PM EDT - 1 year ago

Allakos Inc. Allegations: Schall Law Firm Initiates Probe and Invites Affected Investors to Connect

Jun 4, 2024, 3:00 PM EDT - 1 year ago

The Schall Law Firm is Initiating a Probe into Allegations Against Allakos Inc. and Invites Investors who have Suffered losses to Get in Touch

Jun 3, 2024, 4:55 PM EDT - 1 year ago

ALLK IMPORTANT ACTION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

Jun 2, 2024, 11:00 AM EDT - 1 year ago

IMPORTANT ACTION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

May 31, 2024, 6:00 PM EDT - 1 year ago

IMPORTANT ACTION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

May 28, 2024, 7:02 AM EDT - 1 year ago

Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

May 17, 2024, 1:15 PM EDT - 1 year ago

IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

May 9, 2024, 4:02 PM EDT - 1 year ago

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

Mar 14, 2024, 4:02 PM EDT - 2 years ago

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 7:02 AM EST - 2 years ago

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

Feb 12, 2024, 7:02 AM EST - 2 years ago

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

Feb 6, 2024, 4:00 AM EST - 2 years ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

Jan 16, 2024, 7:30 AM EST - 2 years ago

Allakos to stop further development of skin disease drug, plans job cuts

Jan 16, 2024, 7:02 AM EST - 2 years ago

Allakos Announces a Restructuring to Focus on Development of AK006

Nov 13, 2023, 4:02 PM EST - 2 years ago

Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

Sep 18, 2023, 2:07 AM EDT - 2 years ago

Scratching The Surface: Allakos' Novel Take On Urticaria

Aug 30, 2023, 4:05 PM EDT - 2 years ago

Allakos Appoints Neil Graham to its Board of Directors

Holymoly1269 Sep. 5 at 2:52 PM

$CMMB $ALLK

0 · Reply

nUme22 Jul. 30 at 12:43 PM

$ALLK money laundering scheme.. once done, they let these die in 3-5 yrs later . Thats it , nothing else

0 · Reply

Gainz4life Jun. 5 at 5:06 PM

$ALLK ive had this shit so long, but i didn't even realize it fell off my charts till today. $4500 gone. Fuck these guys.

0 · Reply

Swisstrad May. 28 at 1:37 PM

$ALLK question... what happen to traders who not sign - money lost?

0 · Reply

Estimize May. 19 at 10:00 AM

Wall St is expecting -0.30 EPS for $ALLK Q1 [Reporting 05/21 AMC] http://www.estimize.com/intro/allk?chart=historical&metric_name=eps&utm_c

0 · Reply

BEATWALLSTREET May. 16 at 9:07 PM

$ALLK what a scam this was. Raised close to one billion and sell it for 35 million

0 · Reply

Rage_Against_The_Machine May. 15 at 1:17 PM

0 · Reply

Love_To_Learn May. 15 at 10:32 AM

$ALLK finishing $STTO @zsk78 0.33**** which will be key today on all stocks in the market !

2 · Reply

WAYWARD_SUN May. 15 at 12:02 AM

$ALLK

0 · Reply

JrChase May. 14 at 9:05 AM

$GRYP is doing what $ALLK is doing… you can buy into ($ALLK) if you want…. $ALLK TARGET Projection $8🎯

0 · Reply

Estimize May. 12 at 10:03 AM

Wall St is expecting -0.30 EPS for $ALLK Q1 [Reporting 05/14 AMC] http://www.estimize.com/intro/allk?chart=historical&metric_name=eps&utm_c

0 · Reply

Estimize May. 8 at 8:00 PM

Wall St is expecting -0.19 EPS for $ALLK Q2 [Reporting 08/06 AMC] http://www.estimize.com/intro/allk?chart=historical&metric_name=eps&utm_c

0 · Reply

isEEu28 Apr. 29 at 6:09 PM

$SUNE and $ALLK have the least movement in my portfolio 😡 🧐 🤔

0 · Reply

ponderousbull Apr. 28 at 8:28 PM

$ALLK so when is the merger completed?

0 · Reply

FORMER Apr. 15 at 11:55 AM

$ALLK On 12/5 Institutional Shares were 73,756,678 - 82.55% and today (4/15) Institutional Shares are now 75,318,708 - 84.30% 🤙

0 · Reply

jesstrade1103 Apr. 8 at 3:18 PM

$ALLK so this is stuck at .31 cents until April 15th?

1 · Reply

BEATWALLSTREET Apr. 7 at 2:33 PM

$ALLK i got a sell order for .33 and hasn't been filled yet. I don't get it . Did they buy it for .33 or did not?

0 · Reply

Winning_calls Apr. 7 at 2:35 AM

$ALLK pick me up @ .34

1 · Reply

joe77w Apr. 3 at 12:05 PM

$ALLK not.

1 · Reply

BallinBearBull Apr. 2 at 9:50 PM

$ALLK is Concentra Bio publicly traded?

1 · Reply

Market Cap	29.74M
Revenue (ttm)	0.00
Net Income (ttm)	-115.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	725,800
Avg Vol	1,250,590
Day's Range	N/A - N/A
Shares Out	90.38M
Stochastic %K	89%
Beta	0.15
Analysts	Hold
Price Target	$0.34